Clinical efficacy of allogeneic hematopoietic cell transplantation (HCT) using reduced-intensity conditioning (RIC) for younger patients remains unclear. We therefore performed a retrospective registry-based study to evaluate outcomes for patients with AML aged between 16 and 49 years who underwent RIC allogeneic HCT. Patients receiving RIC (N = 125) showed significantly worse survival than those receiving myeloablative conditioning (MAC; N = 1,554) (47.7% for RIC and 54.2% for MAC at 4 years, P = 0.047). However, the difference became marginal after adjustment for patient characteristics (P = 0.080), and inclusion in the multivariate analysis of the HCT comorbidity index or the propensity score for estimating the likelihood of choosing RIC or MAC further reduced statistical significance (P = 0.371 and 0.206, respectively), indicating the existence of a selection bias against RIC. Nevertheless, outcomes for our patients receiving RIC were still acceptable, so that RIC constitutes a potential therapeutic option for younger AML patients who are deemed unsuitable for MAC. Subgroup analyses showed that patients aged between 40 and 49 years as well as those in first or second CR at the time of transplantation exhibited similar outcomes regardless of whether they were treated with RIC or MAC.
INTRODUCTION
Although allogeneic hematopoietic cell transplantation (HCT) is the most potent therapy for preventing relapse of AML, the substantial risk of treatment-related mortality has historically limited its use to younger patients. 1, 2 However, the situation has changed greatly since the development of reduced-intensity conditioning (RIC). Because of its reduced toxicity, the introduction of RIC has expanded the applicability of allogeneic HCT to patients who would previously not have been candidates for this procedure when only conventional myeloablative conditioning (MAC) was available. In recent years, several studies have been conducted to compare RIC and MAC mostly for older patients and reported similar post-transplantation survival, [3] [4] [5] [6] [7] [8] [9] [10] [11] resulting in a steadily increasing use of RIC instead of MAC. This contrasts with its use for younger patients, for whom MAC remains a conditioning of choice primarily because clinical experience with RIC is less plentiful for these patients. We therefore conducted a large-scale registry-based study to evaluate outcomes for younger patients with AML who underwent RIC allogeneic HCT from a matched related or unrelated donor. Given the potential differences in the baseline characteristics between patients receiving MAC and RIC, we performed multivariate analysis with or without adjustment for the propensity score to accurately estimate the prognostic impact of conditioning intensity. A propensity score system is a statistical technique that is used to compare the outcomes of patients whose treatments were not assigned randomly. 12, 13 In this study, the propensity score for an individual patient was defined as a conditional probability of being treated with MAC or RIC, which was calculated based on his/her background characteristics. By using this methodology, we attempted to control the potential confounders in a non-randomized comparison.
PATIENTS AND METHODS

Data source
All data were collected through the Transplant Registry Unified Management Program sponsored by the Japanese Society for Hematopoietic Cell Transplantation and the Japanese Data Center for Hematopoietic Cell Transplantation. This registration program covers nearly all transplantation centers nationwide, and each participating center is required to report annually follow-up information for consecutively registered autologous and allogeneic HCTs. 14, 15 Study population Patients with AML (not including acute promyelocytic leukemia) whose conditioning intensity could be determined as MAC or RIC according to the criteria detailed in the next section were selected from the Transplant Registry Unified Management Program database. Moreover, they had to be between 16 Toranomon Hospital, Tokyo, Japan; 10 HLA-matched sibling (6/6 matched at the serological level) or unrelated (8/8 matched at the allele level) donor. Patients who received umbilical cord blood transplantation were excluded. The institutional review board of the Fujita Health University School of Medicine approved this study.
Definitions
The conditioning intensity was classified in line with the published criteria. 16, 17 MAC included (1) single-dose of TBI45 Gy or fractionated TBI48 Gy; (2) oral busulfan (BU)49 mg/kg or IV BU47.2 mg/kg; and (3) melphalan (MEL)4140 mg/m 2 . RIC included regimens that did not meet the criteria for MAC or non-myeloablative conditioning (that is, (1) TBI p 2 Gy with or without purine analog; (2) fludarabine (FLU) and cyclophosphamide (CY)-based regimen; (3) FLU, cytarabine (AraC) and idarubicin; and (4) cladribine and AraC). Neutrophil engraftment was defined as successful if a neutrophil count of at least 0.5 × 10 9 /L was attained for two consecutive days, and platelet engraftment as successful if a platelet count of at least 50 × 10 9 /L independent of transfusions was attained for two consecutive days. Acute and chronic GvHD were assessed according to the standard criteria. 18, 19 For the analysis of chronic GvHD, only those patients who survived 100 days post-transplantation without relapse were included. Cytogenetic risk was classified in accordance with the revised Medical Research Council criteria. 20 The HCT comorbidity index (HCT-CI) was used to assess pre-transplantation comorbidities. 21 
Statistical analysis
Distributions of characteristics of patients in the RIC and MAC groups were compared by using the χ 2 -test for categorical variables, and the Wilcoxon rank-sum test for continuous variables. Overall survival (OS) was defined as the time from transplantation to death or last visit. The probability of OS was estimated with the aid of the Kaplan-Meier estimator, and differences between groups were analyzed with the log-rank test. To evaluate the independent effect of conditioning intensity, multivariate analysis was performed with the inclusion of all covariates listed in Table 1 in the final model. We did not use a model selection approach because of the concern about a potential confounding effect of each of these variables. The Cox proportional hazards regression model was used for estimation of hazard ratios (HRs) and 95% confidence intervals (CIs). Given the inherent difference in patient characteristics between the RIC and MAC groups, we took a propensity score into account to adjust for factors that affect the choice between RIC and MAC. The propensity score for estimating the likelihood of choosing either type of conditioning was calculated using a logistic regression model in which treatment selection was regressed on the baseline covariates listed in Table 1 . Each patient was assigned a score in the range of 0-1 (0 for a definite choice of MAC and 1 for RIC), which was used for continuous adjustment in multivariate analysis. Relapse and non-relapse mortality were considered to be mutually competing risk events. Incidence of relapse and non-relapse mortality was estimated with the aid of the cumulative incidence estimator, and differences between groups were analyzed with the Gray Abbreviations: CR = complete remission; ECOG = Eastern Cooperative Oncology Group; GvHD = graft-versus-host disease; MAC = myeloablative conditioning; RIC = reduced-intensity conditioning. test. Multivariate regression models were constructed using the model of Fine and Gray. Cumulative incidence of engraftment and GvHD was also calculated by taking into account competing risks (death for engraftment, and death and relapse for GvHD).
RESULTS
Patient characteristics
A total of 1679 patients met the eligibility criteria for this study, consisting of 1554 patients having received MAC and 125 RIC. The median follow-up period for surviving patients was 3.8 years (range, 0.0-11.4 years) for the MAC group and 4.2 years (range, 0.5-11.1 years) for the RIC group. Table 1 summarizes baseline characteristics of patients in the two groups. Compared with those in the MAC group, patients in the RIC group were older (P o 0.001), and were more likely to have a sibling donor (P = 0.006) and peripheral blood as a stem cell source (P = 0.034). The RIC group tended to have a worse Eastern Cooperative Oncology Group (ECOG) performance status (P = 0.077).
Engraftment and GvHD
There was no difference in hematopoietic recovery between the groups; cumulative incidence of neutrophil engraftment at day 100 was 93.6% for the RIC group and 97.5% for the MAC group (P = 0.980), and that of platelet engraftment was 78.4% for the RIC group and 88.2% for the MAC group (P = 0.253). There was no significant difference either in the cumulative incidence of grades II-IV acute GvHD (28.5% for the RIC group vs 32.5% for the MAC group at day 100, P = 0.282) or chronic GvHD (38.2% for the RIC group vs 41.5% for the MAC group at 4 years, P = 0.282).
Overall survival, relapse and non-relapse mortality Figure 1 shows OS, relapse and non-relapse mortality for the RIC and MAC groups. Patients receiving RIC showed significantly worse survival than those receiving MAC (47.7% for RIC and 54.2% for MAC at 4 years, P = 0.047; Figure 1a ). There was no significant difference in the cumulative incidence of relapse (40.9% for RIC and 35.5% for MAC at 4 years, P = 0.380; Figure 1b ) and non-relapse mortality (17.4% for RIC and 14.9% for MAC at 4 years, P = 0.170; Figure 1c) , both of which remained non-significant after adjustment for other covariates including age and ECOG performance status for multivariate analysis. (Tables 2 and 3) . A marginally adverse effect of RIC on OS was found in a multivariate model (P = 0.080, Table 4), although this association was eliminated when the propensity score for estimating the likelihood of choosing either type of conditioning was added to the Cox model (P = 0.206, Supplementary Table 1) .
Survival analysis in terms of HCT-CI HCT-CI scores could be obtained for 95 patients (76%) in the RIC group and 1076 patients (69%) in the MAC group. Distributions of the scores differed significantly between the groups (P o 0.001); patients with an HCT-CI score ⩾ 3 accounted for 23% in the RIC group versus 9% in the MAC group, whereas those with a score of 0 accounted for 44% in the RIC group versus 70% in the MAC group. When the HCT-CI was included in the Cox model, the effect of conditioning intensity on OS was no longer significant (P = 0.371; Supplementary Table 2 ). Compared Abbreviations: CI = confidence interval; CR = complete remission; ECOG = Eastern Cooperative Oncology Group; GvHD = graft-versus-host disease; HR = hazard ratio; MAC = myeloablative conditioning; RIC = reduced-intensity conditioning. Abbreviations: CI = confidence interval; CR = complete remission; ECOG = Eastern Cooperative Oncology Group; GvHD = graft-versus-host disease; HR = hazard ratio; MAC = myeloablative conditioning; RIC = reduced-intensity conditioning.
RIC-HCT for younger patients with AML M Yanada et al
with those with an HCT-CI score of 0, patients with an HCT-CI score of 1-2 or ⩾ 3 were at significantly higher risk of death (P = 0.038 and P = 0.003, respectively; Supplementary Table 2) .
Subgroup analysis
We also attempted to identify patients who were less likely to suffer from the disadvantages of RIC. Figure 2 shows forest plots summarizing results of univariate analysis for OS by subgroup. Although all of the subgroups shown here had an HR higher than 1.0 (that is, inferior OS with RIC), there were only two groups of patients whose HR was less than 1. Figure 3 shows survival curves by age (younger or older than 40 years) for patients receiving RIC and MAC, and Figure 4 by disease status (CR1/CR2 or more advanced disease) at the time of transplantation.
DISCUSSION
There have been several retrospective studies and a few prospective studies to compare the efficacy of RIC and MAC allogeneic HCT for patients with AML. [3] [4] [5] [6] [7] [8] [9] [10] [11] Some of them reported similar outcomes for RIC and MAC in terms of relapse, non-relapse mortality and OS, whereas others reported a lower incidence of non-relapse mortality with RIC, which was generally offset by a higher incidence of relapse, eventually resulting in similar OS. However, because these previous studies predominantly included older patients, it has remained unclear whether RIC allogeneic HCT is useful for younger patients.
This Japanese nationwide survey showed significantly worse survival with RIC compared with MAC allogeneic HCT for AML patients younger than 50 years. Nevertheless, this difference in effect became marginally significant after adjustment for baseline characteristics of patients, and inclusion of the HCT-CI or the propensity score for estimating the likelihood of choosing RIC or MAC in the multivariate model further reduced statistical significance. These findings suggest that our comparison between RIC and MAC was affected by both known and unknown confounding factors. As for the former factors, the patients in the RIC group were older, presented with higher HCT-CI scores, and tended to have a worse ECOG performance status. Given that MAC is the gold standard for younger patients, most of the patients in the RIC group must have been considered unsuitable for MAC for some reason. The similar incidence of non-relapse mortality for the RIC and MAC groups could be explained at least partly by selection bias. In this context, it should be emphasized that, even though such a selection bias exists, our patients in the RIC group showed acceptable post-transplantation outcomes, with a 4-year OS rate of 47.7%. Although HCT-CI scores were available for only~70% of our patients, they were distributed disproportionately between those receiving RIC and MAC and also correlated with OS, suggesting the relevance of considering the HCT-CI when analyzing the outcomes of allogeneic HCT. With regard to other intergroup imbalances, patients in the RIC group were less likely to receive transplantations from an unrelated donor and more likely to have peripheral blood as a stem cell source, both of which are well-known factors associated with the development of GvHD. [22] [23] [24] [25] We did not observe significant differences in the cumulative incidence of acute and chronic GvHD between patients receiving RIC and MAC; however, this needs to be cautiously interpreted because peripheral blood stem cell transplantations from an unrelated donor had scarcely been performed in Japan during the study period.
Further emphasis should be placed on the findings that certain subgroups had similar outcomes regardless of whether they were treated with RIC or MAC. Our results therefore indicate that (1) RIC is an acceptable option for younger patients considered unsuitable for MAC, and (2) certain subsets of patients, namely, those aged between 40 and 49 years and those in CR1 or CR2 at the time of transplantation, are less likely to suffer possible disadvantages of choosing RIC. On this point, Passweg et al. 10 recently analyzed a large-scale data of AML patients aged 40-60 years who underwent allogeneic HCT during CR1. Their study revealed that MAC had no advantage over RIC in their middle-aged population, and that RIC even appeared superior in cytogenetically favorable patients. Considering their findings as well as ours, age and disease characteristics may be important factors to determine optimal conditioning intensity.
It would be safe to say that analytical problems arising from the selection bias can be resolved only by careful examination of the findings of a randomized controlled study. To the best of our knowledge, two such studies have been conducted to compare RIC and MAC for patients with AML. 6, 9 One German study randomized patients aged 18-60 years with AML in CR1 to either FLU/TBI of 8 Gy or CY/TBI of 12 Gy. 6 After 3 years, no significant intergroup differences were observed in relapse (28% for RIC vs 26% for MAC), non-relapse mortality (13% for RIC vs 18% for MAC), or OS (61% for RIC vs 58% for MAC). The other study conducted in the US randomized patients aged 18-65 years with AML or MDS having fewer than 5% myeloblasts in the bone marrow to RIC (FLU/BU or FLU/MEL) or MAC (BU/CY, FLU/BU or CY/TBI). 9 Although published only in abstract form at the present time, the study found that at 18 months the RIC arm yielded a lower incidence of non-relapse mortality (4.4% for RIC vs 15.8% for MAC), but that a higher incidence of relapse (48.3% for RIC vs 13.5% for MAC) led to significantly worse RFS (47.3% for RIC vs 67.7% for MAC). The difference in OS did not reach statistical significance (67.7% for RIC vs 77.4% for MAC). The discrepancies between these two randomized controlled studies need to be interpreted taking into consideration the very high relapse rate for the RIC arm in the US study. Our finding is consistent with that of the German study in that we did not observe a greater risk of relapse with RIC for our retrospective cohort. A detailed report of the US study clarifying this discrepancy with the other studies is eagerly awaited. Abbreviations: CI = confidence interval; CR = complete remission; ECOG = Eastern Cooperative Oncology Group; GvHD = graft-versus-host disease; HR = hazard ratio; MAC = myeloablative conditioning; OS = overall survival; RIC = reduced-intensity conditioning. In addition to the selection bias, the relatively small number of patients in the RIC group constitutes another limitation of our study. Only 7.4% (125/1679) of the analyzed patients received RIC, which reflects the fact that using RIC for younger patients has not been common practice in Japan. This situation must have formed the basis of the selection bias, that is, most patients receiving RIC may have had a special reason to give up on MAC, which is supported by our propensity score-adjusted analysis where the likelihood of choosing RIC or MAC was taken into consideration. Although a prospective randomized study is undoubtedly the only way to solve this issue, it should be remembered that patients entered into a prospective randomized study are fit enough to meet predefined inclusion and exclusion criteria strictly, and thus they do not represent the general patient population. 26 For this reason, a large-scale registry-based study like ours can provide the requisite real-world data, and its findings should be used to complement those of a prospective randomized study.
To summarize, this registry-based study confirmed the existence of a considerable selection bias for a retrospective comparison of RIC and MAC. Despite such a selection bias, our data showed that outcomes with RIC were still acceptable for younger patients with AML, which confirmed that RIC allogeneic HCT constitutes a potential therapeutic option for those who are deemed unsuitable for MAC allogeneic HCT. Our subgroup analyses suggest that patients aged 40-49 years are better candidates for RIC than those younger than 40 years, as are those in CR1 or CR2 at the time of transplantation rather than those in advanced disease. Given the lack of compelling evidence to support superiority of RIC over MAC in younger patients, MAC remains the conditioning of choice especially if they are fit enough to receive MAC, but this deserves to be challenged in future studies. 
